Topics

Research

Moderna loses challenge to Arbutus patent on vaccine technology

Moderna loses challenge to Arbutus patent on vaccine technology

By: Jan Wolfe
Source: Reuters
Date of Publication: July 23rd, 2020
Shares of Moderna Inc fell nearly 10% after it lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna’s efforts to develop next-generation vaccines, including a coronavirus vaccine.
Gilead’s next COVID-19 treatment advancement could keep patients out of hospitals

Gilead’s next COVID-19 treatment advancement could keep patients out of hospitals

By: Sy Mukherjee
Source: Fortune
Date of Publication: June 22nd, 2020
Gilead won the first Food and Drug Administration (FDA) emergency authorization for a COVID-19 treatment in May. Now, the biotech giant says, it will soon begin clinical trials for a different version of the same experimental drug, remdesivir, which might make it easier to administer outside of a hospital or ICU wing.
'Brands Are Really Going To Be Judged.' Companies Are Walking a Tightrope During the COVID-19 Pandemic

'Brands Are Really Going To Be Judged.' Companies Are Walking a Tightrope During the COVID-19 Pandemic

By: Katy Steinmetz
Source: Time Magazine
Date of Publication: April 2nd, 2020
Like just about everyone, Hotels.com had to change plans when the pandemic arrived.
J&J to begin human trials of COVID-19 vaccine in second half of July

J&J to begin human trials of COVID-19 vaccine in second half of July

By: Saumya Sibi Joseph
Source: Reuters
Date of Publication: June 10th, 2020
Johnson & Johnson said on Wednesday it would start human trials of its potential COVID-19 vaccine in the second half of July, two months earlier than planned, as drugmakers race to develop a shot for the deadly respiratory disease.
AstraZeneca lays out plan for producing 2 billion doses of Covid-19 vaccine, if it works

AstraZeneca lays out plan for producing 2 billion doses of Covid-19 vaccine, if it works

By: Matthew Herper
Source: Stat News
Date of Publication: June 4th, 2020
The drug giant AstraZeneca said Thursday that it has found partners to manufacture and distribute 2 billion doses of the experimental Covid-19 vaccine created by Oxford University, inking a series of deals with non-government organizations and another manufacturer.
A COVID-19 vaccine has passed its first human trial. But is it the frontrunner?

A COVID-19 vaccine has passed its first human trial. But is it the frontrunner?

By: Nsikan Akpan
Source: National Geographic
Date of Publication: May 29th, 2020
Moderna Therapeutics has just entered phase two of its clinical trials. Here's how mRNA vaccines work and what the latest developments mean.
Eli Lilly starts human study of a potential coronavirus treatment

Eli Lilly starts human study of a potential coronavirus treatment

By: Reuters
Source: CNBC
Date of Publication: June 1st, 2020
Eli Lilly said on Monday it had started an early-stage trial to test its potential treatment for Covid-19, in the world’s first study of an antibody treatment against the disease.
Rabin Martin Covid19 briefing

Rabin Martin Covid19 briefing

By: Rabin Martin
Source: Page Society
Date of Publication: May 7th, 2020
On Monday, May 4, world leaders and philanthropic organizations pledged $8.1 billion to the COVID-19 response to support research, manufacturing and distribution of possible diagnostics, vaccines and treatments. Spearheaded by the European Union, the pledging event brought leaders together virtually to highlight the critical need for international cooperation to mitigate the crisis. The U.S., conspicuous by its absence, did not contribute to this coordinated financing pool.
Hot Topics: COVID-19 from the Healthcare Perspective

Hot Topics: COVID-19 from the Healthcare Perspective

By: Page Society
Source: Page Society
Date of Publication: May 7th, 2020
To offer a window into these aspects of COVID-19 response, Page held a Hot Topics call for Page and Page Up members featuring perspectives from several organizations - a healthcare system that treated the first COVID-19 patient in the U.S., one of the largest national clinical laboratories in the U.S., a leader in RNA-based drug discovery and a leader in messenger RNA-based vaccines. Here are some takeaways from that discussion, led by Orest Holubec, chief communication officer for Providence.
Johnson&Johnson_vaccine

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

By: Johnson & Johnson
Source: Johnson & Johnson
Date of Publication: March 30th, 2020
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020. Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply